Compositions and methods for the prevention and treatment of cardiovascular diseases
Inventors
Van Wyk, Henk • Van Wyk, Mariette • Krebs, Trace • Lange, Peter • Denomme, Brian • Volk, Michael A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9775798-B2
Publication Date
2017-10-03
Expiration Date
Abstract
Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
Core Innovation
The invention relates to electro-activated aqueous compositions and methods for treating dysfunctional cardiovascular conditions in a subject. The electro-activated solution is characterized by a stable oxidation-reduction potential (ORP) in the range between -250 mV and +2500 mV for a period of at least 12 months, a conductivity in the range between 11 and 15 mS/cm, and a pH in the range between 6.5 and 7.6.
The composition comprises electro-activated water together with magnesium sulfate hexahydrate, sodium bicarbonate, ascorbic acid, niacinamide, pyridoxine HCl, calcium D pantothenate, thiamin HCl, riboflavin, cyanocobalamin, and 2-diethylaminoethanol in defined ranges. The stable composition is suitable for maintenance of the electro-activated solution characteristics over an extended period.
The treatment method administers the stable composition by parenteral injection to a subject having a calcium score of 46 and above or diagnosed with Buerger’s Disease. The cited administration routes include intravenous and intra-arterial delivery, and the content includes a mechanistic rationale linking electro-activated solutions to reactive oxygen species (ROS) and cellular membrane effects, including trans membrane potential and related cellular permeability.
Claims Coverage
The document contains one independent claim directed to a parenteral treatment method using a stable electro-activated solution with specified ORP, conductivity, and pH values, together with defined ingredient ranges. Dependent claims refine the treated population and administration route, specifically narrowing delivery to intra-arterial or intravenous and targeting subjects with calcium score ≥46 or with a Buerger’s Disease diagnosis.
Parenteral administration of stable electro-activated solution with defined ORP, conductivity, and pH
Administering by parenteral injection to a subject a stable composition comprising a therapeutically effective amount of an electro-activated solution having ORP between -250 mV and +2500 mV for a period of at least 12 months, conductivity between 11 and 15 mS/cm, and pH between 6.5 and 7.6.
Defined ingredient ranges for an electro-activated composition
The electro-activated solution comprises magnesium sulfate hexahydrate, sodium bicarbonate, ascorbic acid, niacinamide, pyridocxin HCL, calcium D pantothenate, thiamin HCl, riboflavin, cyanocobalamin, 2-di-ethylaminoethanol, and electro-activated water in defined ranges.
Treatment target based on calcium score ≥46 or Buerger’s Disease
Treating a subject having a calcium score of 46 and above or diagnosed with Buerger’s Disease.
Intra-arterial or intravenous administration routes
Administering the composition of the method by an intra-arterial or intravenous route.
Claim coverage centers on administering a stable electro-activated solution composition by parenteral injection, where the electro-activated solution is defined by long-term stable ORP (-250 mV to +2500 mV for at least 12 months), conductivity (11–15 mS/cm), and pH (6.5–7.6), and is further defined by specific ingredient ranges. Dependent claims narrow the treated population to calcium score ≥46 or refine the parenteral delivery route to intra-arterial or intravenous and apply the method to subjects diagnosed with Buerger’s Disease.
Stated Advantages
The stable composition maintains the electro-activated solution characteristics over an extended period.
Documented Applications
Treating a subject having a calcium score of 46 and above using a stable electro-activated solution administered by parenteral injection.
Treating subjects diagnosed with Buerger’s Disease using a stable electro-activated solution administered by parenteral injection, including intravenous or intra-arterial routes.
Use of coronary calcium scan including Agatston calcium score to assess calcium-score outcomes, including reported calcium-score changes in subjects with baseline calcium score ≥46.
Reported angina remission and improved angiograms associated with the administration of the claimed stable electro-activated compositions.
Reported Buerger’s disease symptom resolution associated with the administration of the claimed stable electro-activated compositions.
Interested in licensing this patent?